STOCKHOLM, SWEDEN - October 21, 2011. Oncopeptides AB, a Karolinska Development AB portfolio company, today announced the appointment of Jakob Lindberg as new CEO. Mr. Lindberg holds a Med. Lic. in Molecular Immunology a MSc in pre-clinical medicine from the Karolinska Institutet in Sweden and a BA in Finance and Administration from the Stockholm University. He started his career as an analyst with Merrill Lynch in London and moved to consultancy with McKinsey in Stockholm, followed by a period in Gothenburg as CEO and co-founder of Cellectricon AB. For the last six years, Jakob has been Vice President and Venture Partner at Investor Growth Capital in Stockholm.
"We are very pleased to welcomeJakob to Oncopeptides. The experience he brings will greatly assist the company in the further development of its lead oncology therapeutic candidate”, said Alan Hulme, Chairman of Oncopeptides.
Jakob Lindberg stated "I am very excited to be joining Oncopeptides and to leading the team to take this very promising cytotoxic pro-drug through the later stages of development in collaboration with global partners. As Treanda™ has shown there is a lot of untapped potential in alkylating agents in developing better treatment for cancer patients."
TO THE EDITORS
Oncopeptides AB is a privately held company developing pharmaceuticals to treat cancer. The Company has developed proprietary technology based on creating pro-drugs with increased efficacy of already known and effective cytotoxic compounds. The lead substance, called J1 (melphalan flufenamide) is presently in a phase I/II clinical trialand is currently seeking co-development/licensing partners for the major geographical regions. Oncopeptides is a portfolio company of Karolinska Development AB publ and Stiftelsen Industrifonden.
For further information please contact:
Alan Hulme, Chairman, Oncopeptides AB E-mail: firstname.lastname@example.org. Phone:+44-(0)207-924-4053